Holen Sie sich die Stockscreener-App
6.48
1.41%
0.09
Schlusskurs vom Vortag:
$6.39
Offen:
$6.35
24-Stunden-Volumen:
160.88K
Relative Volume:
0.91
Marktkapitalisierung:
$110.49M
Einnahmen:
$137.27M
Nettoeinkommen (Verlust:
$-123.57M
KGV:
-0.5882
EPS:
-11.016
Netto-Cashflow:
$-102.89M
1W Leistung:
+18.68%
1M Leistung:
+19.12%
6M Leistung:
+46.28%
1J Leistung:
-40.82%
1-Tages-Spanne:
$6.1905
$6.69
1-Wochen-Bereich:
$5.368
$6.69
52-Wochen-Spanne:
$3.51
$12.45
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.48 | 108.96M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm (Nasdaq: KPTI) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - Karyopharm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
[424B3] Karyopharm Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risks2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Why Karyopharm Therapeutics Inc. (25K0) stock trades below fair valueJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
How Karyopharm Therapeutics Inc. stock reacts to job market dataStock Surge & AI Driven Price Predictions - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock undervalued by metrics2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for Karyopharm Therapeutics Inc. stockJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why pension funds invest in Karyopharm Therapeutics Inc. (25K0) stockRate Cut & Technical Pattern Recognition Alerts - newser.com
Can Karyopharm Therapeutics Inc. stock hit record highs againGold Moves & AI Driven Stock Movement Reports - newser.com
Is Karyopharm Therapeutics Inc. stock attractive for long term wealth building2025 Short Interest & Consistent Profit Alerts - newser.com
Can Karyopharm Therapeutics Inc. (25K0) stock sustain revenue momentumMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
What’s the recovery path for long term holders of Karyopharm Therapeutics Inc.July 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Will Karyopharm Therapeutics Inc. (25K0) stock outperform energy sector in 2025Weekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickQuarterly Portfolio Review & Low Risk High Win Rate Picks - newser.com
Quantitative breakdown of Karyopharm Therapeutics Inc. recent moveMarket Performance Report & Real-Time Market Sentiment Alerts - newser.com
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):